A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Selumetinib (Primary) ; Iodine radioactive
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASTRA
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned End Date changed from 1 May 2019 to 5 Jul 2019.
- 01 Mar 2017 Planned primary completion date changed from 1 Nov 2017 to 8 Jan 2018.